ALLR logo

ALLARITY THERAPEUTICS INC

ALLRNASDAQ
🏆 #4862 by market capEarnings Nov 14US Equity
$310.83▼ $3.36 (−1.08%)
Simulated price
🔔
Track ALLR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.1%
7d▲ 28157.3%
14d▲ 26928.7%
30d▲ 21636.4%
ytd▲ 29787.5%
1y▲ 19825.0%
🏦Market Cap
$15M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
107.5%
High
💵FCF Margin
-3994.8%
Thin
⚖️P/S Ratio
44.5x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$309.85 – $312.49
52-Week Range
$0.77 – $1.84
Volume
$3.46B
Avg Volume
$4.11B
Shares Outstanding
15.9M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$320,000
Last Q Revenue
$74,689
P/E Ratio
-1.2
P/S Ratio
44.5x
EPS (TTM)
$-0.78
Dividend Yield
0.00%
Dilution (1yr)
+96.9%

Why Investors Own ALLR

  • ✓High-growth profile — revenue up +17.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 79% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALLR logo

ALLARITY THERAPEUTICS INC

ALLR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$320K▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −53.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$15M▼ −16.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
14.4M▲ +96.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13M▼ −$5M YoY
StockOtter · stockotter.space

About ALLARITY THERAPEUTICS INC

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$384.09
▲ +23.6% Upside
High Target$455.99
Low Target$359.35
Based on 29 analysts

Latest News & Updates

🚀
Barron’s·2h ago

ALLARITY THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ALLR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ALLARITY THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.